Physician profile
John Beabout
NPI 1225429129
$7,327.59
in general payments reported to CMS, 2019-2025
29 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $2,599 · 2023: $3,077 · 2024: $1,000 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Travel and Lodging: $664 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,712.80 |
| Travel and Lodging | $663.70 |
| Education | $126.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,705.01 | 2022-2023 | Interstim |
| Axonics, INC. | $1,296.43 | 2021-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $739.76 | 2021-2024 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $710.42 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $494.06 | 2022-2025 | |
| Janssen Biotech, INC. | $472.30 | 2021-2024 | Erleada |
| Endo Pharmaceuticals INC. | $294.33 | 2021-2024 | Xiaflex, Aveed |
| Tolmar, INC. | $194.71 | 2023-2025 | Eligard, Jatenzo |
| Antares Pharma, INC. | $188.42 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Urovant Sciences INC | $172.04 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $152.58 | 2021-2023 | Provenge |
| Pfizer INC. | $123.02 | 2024-2025 | |
| Hollister Incorporated | $118.45 | 2022-2023 | Infyna Chic |
| Bayer Healthcare Pharmaceuticals INC. | $108.02 | 2021-2023 | |
| Teleflex LLC | $101.53 | 2022-2023 | Urolift |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.66 | 2022-2023 | Keytruda |
| Olympus America INC. | $54.97 | 2022-2025 | Itind System |
| Endo USA, INC. | $47.48 | 2024 | Xiaflex |
| Calyxo, INC. | $43.92 | 2025 | Cvac Aspiration System |
| Tolmar Pharmaceuticals, INC. | $43.11 | 2021-2022 | |
| Urogen Pharma, INC. | $35.09 | 2022-2023 | Jelmyto |
| C. R. Bard, INC. & Subsidiaries | $33.71 | 2022 | |
| 180 Medical, INC. | $29.63 | 2024 | |
| Progenics Pharmaceuticals, INC. | $26.14 | 2022 | |
| Boston Scientific Corporation | $20.22 | 2022 | |
| Travere Therapeutics, INC. | $18.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.13 | 2022 | |
| Novo Nordisk INC | $14.63 | 2021 | |
| Verity Pharmaceuticals INC. | $14.54 | 2023 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beabout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.